SLRN Stock Overview
A clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Acelyrin, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.73 |
| 52 Week High | US$29.88 |
| 52 Week Low | US$3.67 |
| Beta | 0 |
| 11 Month Change | 72.56% |
| 3 Month Change | 58.73% |
| 1 Year Change | -72.42% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.36% |
Recent News & Updates
Shareholder Returns
| SLRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.1% | 3.4% | -2.4% |
| 1Y | -72.4% | 17.1% | 17.5% |
Return vs Industry: SLRN underperformed the US Biotechs industry which returned 15.4% over the past year.
Return vs Market: SLRN underperformed the US Market which returned 17.2% over the past year.
Price Volatility
| SLRN volatility | |
|---|---|
| SLRN Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLRN's share price has been volatile over the past 3 months.
Volatility Over Time: SLRN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 135 | Mina Kim | www.acelyrin.com |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.
Acelyrin, Inc. Fundamentals Summary
| SLRN fundamental statistics | |
|---|---|
| Market cap | US$664.47m |
| Earnings (TTM) | -US$240.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs SLRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$240.16m |
| Earnings | -US$240.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLRN perform over the long term?
See historical performance and comparison